Newsstand | Aplastic Anemia & MDS International Foundation

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Newsstand

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Originally Published: 01/09/2020
Abstract BACKGROUND Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2 and SMAD3 signaling, showed promising results in a phase 2 study.   (continued) 

Iron Chelation Therapy May Improve Overall Survival in Patients With Myelodysplastic Syndrome

Originally Published: 01/02/2020
Iron chelation therapy may reduce mortality and leukemia transformation risk among patients with myelodysplastic syndrome (MDS), according to a meta-analysis published in Clinical and Experimental Medicine. Anemia is a common issue among patients with MDS. Red blood cell transfusion can be used to treat anemia in these patients but can also lead to iron overload, which is exacerbated by unrestrained intestinal iron uptake. Iron chelation therapy is sometimes administered to patients with MDS when iron overload occurs, but there is debate as to whether this is a sufficiently safe and...

AML Research Efforts in Full Swing After Decades of Stagnation

Originally Published: 12/27/2019
After decades of few advances and stagnant treatment approaches, which mainly comprised 7+3 chemotherapy, the acute myeloid leukemia (AML) paradigm now has several agents approved, and plenty of ongoing trials are exploring other novel therapies alone and in combination, according to Melissa L. Larson, MD. Several of these research efforts are focused on targeting molecular drivers of disease, such as FLT3 and IDH1/2 mutations.

The Falling, Wandering and Crashing Business of Cancer Treatment Side Effects

Originally Published: 12/26/2019
With neuropathy as a result of treatment comes a whole host of issues. The first one I can think of? Oops, there goes the wine! In more ways than one, actually, as wine is probably one of the last things you can enjoy while undergoing chemo. And not only can you not enjoy it, but when you try to lift that glass onto your kitchen counter, neuropathy will cause you to instead bash it against the edge. Hopefully this was not your special glass. If you try it again while in treatment, pick the cheap old glass you got at a yard sale. No big loss. The bashing goes on for a while but it does get...

Woyach Highlights Progress and Next Steps in CLL Paradigm

Originally Published: 12/26/2019
With therapeutic additions to the treatment paradigm of chronic lymphocytic leukemia (CLL), it is now a question of which regimen to give patients in the frontline setting, explained Jennifer A. Woyach, MD. “In the frontline setting, our new options for targeted therapy include ibrutinib (Imbruvica), acalabrutinib (Calquence), and venetoclax (Venclexta) plus obinutuzumab (Gazyva). We have 3 great targeted therapy options. One of the difficulties right now is that we have such great options. [Which patient] do we choose for which agent?” said Woyach.

December 2019 Foundation Update:  Holiday Edition

Originally Published: 12/20/2019

ASH 2019: Can Rapid Precision Medicine Help Older Adults With AML?

Originally Published: 12/07/2019
When someone is diagnosed with acute myeloid leukemia (AML), doctors typically initiate treatment within 24-48 hours of diagnosis given the aggressive nature of the disease. This urgency to treat precludes the use of ancillary test results, such as genomic profiling, to guide upfront treatment decision making and clinical management. Yet, understanding the genomic alterations associated with a patient’s disease is critical and can help enable oncologists to identify the most effective, targeted treatment options. (con't)

Allogeneic Hematopoietic Cell Transplantation and Other Expensive Cellular Therapies: A Miracle for the Few but Off Limits to Many?

Originally Published: 11/15/2019
The number of patients undergoing allogeneic hematopoietic cell transplantation (HCT) for treatment of malignant and nonmalignant disorders has continued to grow worldwide. (footnotes) Great progress has been made in overcoming HLA/immunologic barriers, but nondonor barriers to HCT persist.(footnote) This represents a major unmet need because HCT is not accessible to everyone who would benefit from it.(footnote)

November 2019 AAMDSIF Update Newsletter

Originally Published: 11/14/2019

Summer 2019 MDS Update

Originally Published: 11/08/2019
Read the latest in what's happening in MDS research, hear from MDS patients and so much more!